Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.78M 6.8M 6.25M 5.83M 11.05M 741M 11.22M 75.06M 29.18M 364M 29.21M 28.58M 1.26B P/E 2026 *
-0.02x
P/E 2027 * -0.02x
Enterprise Value 7.78M 6.8M 6.25M 5.83M 11.05M 741M 11.22M 75.06M 29.18M 364M 29.21M 28.58M 1.26B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 2.22x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+1.50%
1 week-5.27%
Current month+5.19%
1 month-12.53%
3 months-5.59%
6 months-30.05%
Current year-25.93%
1 week 3.8
Extreme 3.8003
4.41
1 month 3.75
Extreme 3.75
4.95
Current year 3.75
Extreme 3.75
7.2
1 year 3.75
Extreme 3.75
7.2
3 years 3.75
Extreme 3.75
31.2
5 years 3.75
Extreme 3.75
385.7
10 years 3.75
Extreme 3.75
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 54 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 54 2024-05-14
Chairman 55 2024-09-03
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

5,000 0.2602%
06-09Free

Chairman

5,000 0.2602%
06-09Free

Director

5,000 0.2602%
Change 5-day change 1-year change 3-year change Capi.($)
+1.50%-5.27%-31.59%-85.22% 7.78M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.73%+7.35%+46.01%+122.12% 24.55B
Weighted average by Cap. +2.46%+6.47%+59.05%+137.70%

Financials

2026 *2027 *
Net sales 1.51M 1.32M 1.21M 1.13M 2.14M 144M 2.18M 14.55M 5.66M 70.61M 5.66M 5.54M 243M 3.5M 3.06M 2.81M 2.62M 4.97M 333M 5.05M 33.76M 13.12M 164M 13.14M 12.86M 564M
Net income -44.52M -38.92M -35.77M -33.34M -63.24M -4.24B -64.19M -429M -167M -2.08B -167M -164M -7.18B -47.5M -41.52M -38.16M -35.57M -67.47M -4.52B -68.49M -458M -178M -2.22B -178M -174M -7.66B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-07-02 US$4.050 +1.50% 4,406
26-07-01 US$3.990 +3.64% 39,570
26-06-30 US$3.850 -1.41% 18,036
26-06-29 US$3.905 -8.66% 79,106
26-06-26 US$4.275 +1.79% 12,146
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.050USD
Average target price
41.00USD
Spread / Average Target
+912.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock